Cargando…

Target volume definition for staple line recurrences of non-small cell lung cancer

BACKGROUND: Staple line (SL) recurrences of non-small cell lung cancer (NSCLC) are commonly treated with radiotherapy (RT), but the target volume definition — whole SL versus focused on recurrence — is unclear. The aim of the study was to determine the appropriate target volume for RT of SL recurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuzhat, Jan, Mukhopadhyay, Nitai D., Weiss, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726443/
https://www.ncbi.nlm.nih.gov/pubmed/34992857
http://dx.doi.org/10.5603/RPOR.a2021.0090
_version_ 1784626324343619584
author Nuzhat, Jan
Mukhopadhyay, Nitai D.
Weiss, Elisabeth
author_facet Nuzhat, Jan
Mukhopadhyay, Nitai D.
Weiss, Elisabeth
author_sort Nuzhat, Jan
collection PubMed
description BACKGROUND: Staple line (SL) recurrences of non-small cell lung cancer (NSCLC) are commonly treated with radiotherapy (RT), but the target volume definition — whole SL versus focused on recurrence — is unclear. The aim of the study was to determine the appropriate target volume for RT of SL recurrences. MATERIALS AND METHODS: Twenty-two consecutive patients (20 stage I, 2 stage II) treated with salvage RT for SL recurrences were retrospectively analyzed. Imaging features at the time of SL recurrence were evaluated to guide target volume definition. RESULTS: SURGERY: All patients had complete tumor resection (wedge resection in 10 (45%) and lobectomy in 12 (55%) patients). 14 (64%) patients had risk factors for recurrence, including surgical margins ≤ 2 cm, angiolymphatic and visceral pleural invasion. SALVAGE RT: After a median 26 months (9–67), all 22 patients developed SL recurrence which was metabolically active on PET in all and biopsy-confirmed in 18/22 (82%) patients. All patients underwent RT targeting the location of the SL recurrence only. 13/22 (59%) patients had additional PE T-negative nodular or linear SL changes that were not included in the irradiated volume. RECURRENCE AFTER RT: After a median 17 months (9–34) 10/22 (45%) patients recurred either regionally 6/10 (60%), in the lungs 4/10 (40%) or distally 3/10 (30%). No patient recurred at the SL. Two-year overall and disease-free survival rates after RT were 71% and 65%, respectively. CONCLUSION: RT to SL recurrences alone results in excellent local control. Additional treatment to reduce regional and distant recurrences should be considered.
format Online
Article
Text
id pubmed-8726443
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Via Medica
record_format MEDLINE/PubMed
spelling pubmed-87264432022-01-05 Target volume definition for staple line recurrences of non-small cell lung cancer Nuzhat, Jan Mukhopadhyay, Nitai D. Weiss, Elisabeth Rep Pract Oncol Radiother Research Paper BACKGROUND: Staple line (SL) recurrences of non-small cell lung cancer (NSCLC) are commonly treated with radiotherapy (RT), but the target volume definition — whole SL versus focused on recurrence — is unclear. The aim of the study was to determine the appropriate target volume for RT of SL recurrences. MATERIALS AND METHODS: Twenty-two consecutive patients (20 stage I, 2 stage II) treated with salvage RT for SL recurrences were retrospectively analyzed. Imaging features at the time of SL recurrence were evaluated to guide target volume definition. RESULTS: SURGERY: All patients had complete tumor resection (wedge resection in 10 (45%) and lobectomy in 12 (55%) patients). 14 (64%) patients had risk factors for recurrence, including surgical margins ≤ 2 cm, angiolymphatic and visceral pleural invasion. SALVAGE RT: After a median 26 months (9–67), all 22 patients developed SL recurrence which was metabolically active on PET in all and biopsy-confirmed in 18/22 (82%) patients. All patients underwent RT targeting the location of the SL recurrence only. 13/22 (59%) patients had additional PE T-negative nodular or linear SL changes that were not included in the irradiated volume. RECURRENCE AFTER RT: After a median 17 months (9–34) 10/22 (45%) patients recurred either regionally 6/10 (60%), in the lungs 4/10 (40%) or distally 3/10 (30%). No patient recurred at the SL. Two-year overall and disease-free survival rates after RT were 71% and 65%, respectively. CONCLUSION: RT to SL recurrences alone results in excellent local control. Additional treatment to reduce regional and distant recurrences should be considered. Via Medica 2021-12-30 /pmc/articles/PMC8726443/ /pubmed/34992857 http://dx.doi.org/10.5603/RPOR.a2021.0090 Text en © 2021 Greater Poland Cancer Centre https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
spellingShingle Research Paper
Nuzhat, Jan
Mukhopadhyay, Nitai D.
Weiss, Elisabeth
Target volume definition for staple line recurrences of non-small cell lung cancer
title Target volume definition for staple line recurrences of non-small cell lung cancer
title_full Target volume definition for staple line recurrences of non-small cell lung cancer
title_fullStr Target volume definition for staple line recurrences of non-small cell lung cancer
title_full_unstemmed Target volume definition for staple line recurrences of non-small cell lung cancer
title_short Target volume definition for staple line recurrences of non-small cell lung cancer
title_sort target volume definition for staple line recurrences of non-small cell lung cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8726443/
https://www.ncbi.nlm.nih.gov/pubmed/34992857
http://dx.doi.org/10.5603/RPOR.a2021.0090
work_keys_str_mv AT nuzhatjan targetvolumedefinitionforstaplelinerecurrencesofnonsmallcelllungcancer
AT mukhopadhyaynitaid targetvolumedefinitionforstaplelinerecurrencesofnonsmallcelllungcancer
AT weisselisabeth targetvolumedefinitionforstaplelinerecurrencesofnonsmallcelllungcancer